{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:20:34Z","timestamp":1785468034589,"version":"3.56.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This meta-analysis aimed to evaluate the efficacy of topical minoxidil-finasteride combination (MFX) versus minoxidil monotherapy (MNX) for male androgenetic alopecia (AGA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Following PRISMA 2020 guidelines, we systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception through May 2025. Methodological quality was assessed using Cochrane Risk of Bias 2.0 tool, with statistical analyses performed using RevMan 5.3 and evidence certainty evaluated through GRADEpro GDT. CRD420251054497.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This meta-analysis of seven RCTs (<jats:italic>N<\/jats:italic>\u202f=\u202f396) demonstrated superior efficacy of topical minoxidil-finasteride combination (MFX) over monotherapy (MNX) for male androgenetic alopecia. Pooled analyses showed clinically meaningful improvements in hair density (MD\u202f=\u202f9.22, <jats:italic>p<\/jats:italic>\u202f=\u202f0.04), hair diameter (MD\u202f=\u202f2.26, <jats:italic>p<\/jats:italic>\u202f=\u202f0.005), and global photographic assessment (MD\u202f=\u202f0.79, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.00001), all exceeding minimal clinically important thresholds. The treatment effect followed a hierarchical pattern, with MFX showing strongest benefits for marked improvement (OR\u202f=\u202f3.29, <jats:italic>p<\/jats:italic>\u202f=\u202f0.015) and more variable results for moderate outcomes. While primary outcomes demonstrated robust effects with moderate certainty evidence, observed heterogeneity in some endpoints and sample size limitations suggest the need for standardized assessment methods and larger confirmatory studies to strengthen these conclusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Topical minoxidil-finasteride combination therapy demonstrates superior efficacy over monotherapy for male AGA, supporting its clinical adoption. However, larger, standardized trials are needed to confirm long-term outcomes and optimize treatment protocols.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251054497<\/jats:ext-link>, identifier CRD420251054497.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1632139","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:13:39Z","timestamp":1759810419000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Yulong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/jdv.17079","article-title":"Common causes of hair loss - clinical manifestations, trichoscopy and therapy","volume":"35","author":"Alessandrini","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jalz.2018.09.003","article-title":"AMYPAD diagnostic and patient management study: Rationale and design","volume":"15","author":"Frisoni","year":"2019","journal-title":"Alzheimers Dement"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jacc.2012.01.069","article-title":"\"on-target\" cardiac effects of anticancer drugs: lessons from new biology","volume":"60","author":"Simons","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.2147\/DDDT.S214907","article-title":"Minoxidil and its use in hair disorders: a review","volume":"13","author":"Suchonwanit","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40265-023-01880-x","article-title":"Androgenetic alopecia: therapy update","volume":"83","author":"Devjani","year":"2023","journal-title":"Drugs"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00403-025-04216-9","article-title":"Randomized controlled trial on the efficacy and safety of the combination therapy of topical 0.1% finasteride -\u202f5% Minoxidil in male androgenetic alopecia","volume":"317","author":"Lubis","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/ijt.ijt_72_22","article-title":"Comparative efficacy of topical finasteride (0.25%) in combination with Minoxidil (5%) against 5% Minoxidil or 0.25% finasteride alone in male androgenetic alopecia","volume":"15","author":"Bharadwaj","year":"2023","journal-title":"Int J Trichology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.envint.2019.04.016","article-title":"GRADE guidelines for environmental and occupational health: a new series of articles in environment international","volume":"128","author":"Morgan","year":"2019","journal-title":"Environ Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"Ed000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.36849\/JDD.7826","article-title":"Efficacy of topical finasteride 0.25% with Minoxidil 5% versus topical Minoxidil 5% alone in treatment of male pattern androgenic alopecia","volume":"23","author":"Asad","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/jocd.15953","article-title":"Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: a prospective, randomized, controlled, assessor blinded, 3-arm, pilot trial","volume":"23","author":"Rossi","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1111\/jdv.15171","article-title":"A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia","volume":"32","author":"Suchonwanit","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4172\/2155-9554.1000253","article-title":"A new topical formulation of Minoxidil and finasteride improves hair growth in men with androgenetic alopecia","volume":"6","author":"Saifuddin Sheikh","year":"2015","journal-title":"J Clin Exp Dermatol Res"},{"key":"ref18","first-page":"1312","article-title":"Efficacy and safety of 3% minoxidil versus combined 3% minoxidil \/ 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study","volume":"95","author":"Tanglertsampan","year":"2012","journal-title":"J Med Assoc Thail"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/exd.12965","article-title":"Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us?","volume":"25","author":"Heilmann-Heimbach","year":"2016","journal-title":"Exp Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2133.2004.05785.x","article-title":"Minoxidil: mechanisms of action on hair growth","volume":"150","author":"Messenger","year":"2004","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3109\/09546634.2013.813011","article-title":"The efficacy and safety of 5\u03b1-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride","volume":"25","author":"Gupta","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jdv.17738","article-title":"Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial","volume":"36","author":"Piraccini","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e13379","DOI":"10.1111\/dth.13379","article-title":"5-alpha reductase inhibitors in androgenetic alopecia: shifting paradigms, current concepts, comparative efficacy, and safety","volume":"33","author":"Dhurat","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamadermatol.2021.5743","article-title":"Relative efficacy of Minoxidil and the 5-\u03b1 reductase inhibitors in androgenetic alopecia treatment of male patients: a network Meta-analysis","volume":"158","author":"Gupta","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2006.05.007","article-title":"The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride","volume":"55","author":"Olsen","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaad.2019.08.060","article-title":"Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial","volume":"82","author":"Ramos","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e13741","DOI":"10.1111\/dth.13741","article-title":"The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta-analysis","volume":"33","author":"Zhou","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1632139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:13:39Z","timestamp":1759810419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1632139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":28,"alternative-id":["10.3389\/fmed.2025.1632139"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1632139","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"article-number":"1632139"}}